Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 abatacept SC plus standard treatment vs standard treatment in active idiopathic inflammatory myopathy
jRCT2080223614Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Autoimmune Myopathies, dermatomyositis (DM), polymyositis (PM) and 3 more comparing Abatacept SC + standard treatment with Placebo SC + standard treatment (2 arms). Started Aug 2017; status: completed.
02
Drugs
abatacept
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)immune-mediated necrotizing myopathy (IMNM)Overlap Myositis (OM)
Beyond the preview
Go deeper on jRCT2080223614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223614.